JOURNAL DESCRIPTION
The Medical Radiology and Radiation Safety journal ISSN 1024-6177 was founded in January 1956 (before December 30, 1993 it was entitled Medical Radiology, ISSN 0025-8334). In 2018, the journal received Online ISSN: 2618-9615 and was registered as an electronic online publication in Roskomnadzor on March 29, 2018. It publishes original research articles which cover questions of radiobiology, radiation medicine, radiation safety, radiation therapy, nuclear medicine and scientific reviews. In general the journal has more than 30 headings and it is of interest for specialists working in thefields of medicine¸ radiation biology, epidemiology, medical physics and technology. Since July 01, 2008 the journal has been published by State Research Center - Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency. The founder from 1956 to the present time is the Ministry of Health of the Russian Federation, and from 2008 to the present time is the Federal Medical Biological Agency.
Members of the editorial board are scientists specializing in the field of radiation biology and medicine, radiation protection, radiation epidemiology, radiation oncology, radiation diagnostics and therapy, nuclear medicine and medical physics. The editorial board consists of academicians (members of the Russian Academy of Science (RAS)), the full member of Academy of Medical Sciences of the Republic of Armenia, corresponding members of the RAS, Doctors of Medicine, professor, candidates and doctors of biological, physical mathematics and engineering sciences. The editorial board is constantly replenished by experts who work in the CIS and foreign countries.
Six issues of the journal are published per year, the volume is 13.5 conventional printed sheets, 88 printer’s sheets, 1.000 copies. The journal has an identical full-text electronic version, which, simultaneously with the printed version and color drawings, is posted on the sites of the Scientific Electronic Library (SEL) and the journal's website. The journal is distributed through the Rospechat Agency under the contract № 7407 of June 16, 2006, through individual buyers and commercial structures. The publication of articles is free.
The journal is included in the List of Russian Reviewed Scientific Journals of the Higher Attestation Commission. Since 2008 the journal has been available on the Internet and indexed in the RISC database which is placed on Web of Science. Since February 2nd, 2018, the journal "Medical Radiology and Radiation Safety" has been indexed in the SCOPUS abstract and citation database.
Brief electronic versions of the Journal have been publicly available since 2005 on the website of the Medical Radiology and Radiation Safety Journal: http://www.medradiol.ru. Since 2011, all issues of the journal as a whole are publicly available, and since 2016 - full-text versions of scientific articles. Since 2005, subscribers can purchase full versions of other articles of any issue only through the National Electronic Library. The editor of the Medical Radiology and Radiation Safety Journal in accordance with the National Electronic Library agreement has been providing the Library with all its production since 2005 until now.
The main working language of the journal is Russian, an additional language is English, which is used to write titles of articles, information about authors, annotations, key words, a list of literature.
Since 2017 the journal Medical Radiology and Radiation Safety has switched to digital identification of publications, assigning to each article the identifier of the digital object (DOI), which greatly accelerated the search for the location of the article on the Internet. In future it is planned to publish the English-language version of the journal Medical Radiology and Radiation Safety for its development. In order to obtain information about the publication activity of the journal in March 2015, a counter of readers' references to the materials posted on the site from 2005 to the present which is placed on the journal's website. During 2015 - 2016 years on average there were no more than 100-170 handlings per day. Publication of a number of articles, as well as electronic versions of profile monographs and collections in the public domain, dramatically increased the number of handlings to the journal's website to 500 - 800 per day, and the total number of visits to the site at the end of 2017 was more than 230.000.
The two-year impact factor of RISC, according to data for 2017, was 0.439, taking into account citation from all sources - 0.570, and the five-year impact factor of RISC - 0.352.
Medical Radiology and Radiation Safety. 2019. Vol. 64. No. 4. P. 41–47
DOI: 10.12737/article_5d1108af5d48d3.68800561
A.V. Boyko1, E.A. Dunaeva1, L.V. Demidova1, B.Yа. Alekseev2, A.V. Leont’ev1,
O.B. Dubovetskaya1, L.G. Serova1
Radiotherapy for Patients with Hydronephrosis–Induced Cervical Cancer
1. P.A. Hersen Moscow Oncology Research Center, Moscow, Russia. E-mail:
This email address is being protected from spambots. You need JavaScript enabled to view it.
;
2. N.A. Lopatkin Research Institute of Urology and Interventional Radiology, Moscow, Russia
A.V. Boyko – Head of Dep., Prof., Dr. Sci. Med., ESTRO Member;
E.A. Dunaeva – Senior Researcher, PhD Med.;
L.V. Demidova – Leading Researcher, Dr. Sci. Med.;
B.Yа. Alekseev – Deputy Director, Dr. Sci. Med., Prof., EAU Member, SIU Member;
A.V. Leont’ev – Head of Dep., PhD Med., EANM Member;
O.B. Dubovetskaya – Research Worker, PhD Med.;
L.G. Serova – Oncologist, PhD Med.
Abstract
Purpose: To justify the expansion of indications for radiation or chemoradiation therapy in patients with primary or recurrent cervical cancer complicated by hydronephrosis by eliminating obstruction of the ureters.
Material and methods: The study included 24 patients who received radiation or chemoradiotherapy from 2012 to 2018. 17 patients among them had primary cervical cancer and the other 7 had a relapse of cervical cancer in small pelvis. In accordance with FIGO and TNM classification (2009), stage IIIB was diagnosed (сT3bN0–1M0) in 16 patients and stage IVB (cT3bN1M1, metastasis in para-aortic lymph nodes) in 1 patient. Prior to the start of special treatment, in all patients was detected one- or two-sided hydronephrosis associated with a neoplastic process and accompanied by varying degrees of impaired parenchymal-excretory function of one of the kidneys.
Results: 11 patients had unilateral stenting, 3 patients had bilateral ureteral stenting, nephrostomy was performed in 9 patients and 1 woman had an ureteral stent installed on one side, nephrostomy was performed on the other side. In 70.8 % (17) patients, the irradiation course was performed without interruption. From 5 to 3 weeks (due to cystitis, endometritis, anemia). In 2 patients, it was not possible to complete the full course of radiotherapy because of the intractable effects of pyelonephritis, they were operated on. In the observation period up to 77 months (average observation time 29 months) 16 patients are alive, 12 of them are without signs of disease recurrence. In 6 patients, the natural passage of urine was restored. In 4 patients, the nephrostomy was replaced with a ureteral stent. In 3 patients with ureteral stents they are replaced. Three patients remain with nephrostomy. Eight women died from the progression of the underlying disease, of these, 6 patients are with recurrent cervical cancer in the pelvis. Note that in all 6 patients, as a result of the irradiation, a pronounced palliative effect was achieved in the form of relief of pain and bleeding.
Conclusion: Performing adequate drainage of the ureter(s) allows to expand the indications for radiotherapy or chemoradiation therapy under the radical program in patients with primary or recurrent cervical cancer.
Key words: radiotherapy, cervical cancer, locally advanced and recurrent, hydronephrosis, urine diversion
REFERENCES
1. Clinical recommendations. Cervical cancer. The association of Russian oncologists. 2017. ID: KP537 [cited 2018 Dec 27] Available from: http://cancerlink.ru/cancer/clinical-guidelines-oncology-2017/clinical-guidelines-aor-2017 . (Russian).
2. NCCN (National Comprehensive Cancer Network, OCT 2017) (version 1.2019) Available at nccn.org. [cited 2018 Nov 05]
3. TNM classification of malignant tumours. Sobin LH, Gospodarowicz MK, Wittekind C, eds. 7th ed. NY: Springer-Verlag, 2010. 256 p.
4. Kaprin AD, Titova VA, Kostin AA, Rerberg AG. Improving the Diagnosis and Treatment of Retention Disorders of the Upper Urinary Tract in Patients with Stages IIB–III cancer of the Cervix Uteri. Cancer Urology. 2012;8(2):98-101. DOI: 10.17650/1726-9776-2012-8-2-98-101. (Russian).
5. Rose PG, Ali S, Whitney CW, Lanciano R, Stehman FB. Impact of hydronephrosis on outcome of stage IIIB cervical cancer patients with disease limited to the pelvis, treated with radiation and concurrent chemotherapy: A Gynecologic Oncology Group study. Gynecol Oncol. 2010; 117(2):270-5. DOI: 10.1016/j.ygyno.2010.01.045.
6. Goklu MR, Seckin KD, Togrul C, Goklu Y, Tahaoglu AE, Oz M, et al. Effect of hydronephrosis on survival in advanced stage cervical cancer. Asian Pac J Cancer Prev. 2015;16(10):4219-22. DOI:10.7314/APJCP.2015.16.10.4219
7. Beckta JM, Carter JS, Wan W, Chafe WE, Abayomi OK, Proper MA, et al. Urinary Diversion in the Management of Locally Advanced Cervical Cancer Facilitates the Use of Aggressive Therapy without Adversely Effecting Overall Treatment Time. EC Gynaecology. 2016;3(1): 225-31.
8. Mankad M, Mishra K, Desai A, Patel S. Role of percutaneous nephrostomy in advanced cervical carcinoma with obstructive uropathy: a case series. Indian J Palliat Care. 2009;15(1):37-40.
9. Chepurov AK, Zenkov SS, Mamaev NE, Pronkin EA. Prolonged drainage by ureteral stents: current state of the issue and prospects. Andrology and Genital Surgery. 2009;(2):44-8. (Russian).
10. Pecorelli S. Revised FIGO staging for carcinoma of vulva, cervix, and endometrium. Int J Gynec Obstet. 2009;(105):103-4.
11. Kaprin AD, Titova VA, Kreynina YuM, Kostin AA. Urological complications in oncologic practice: diagnosis, interventional and conservative correction. Moscow; 2011. 168 p. (Russian).
12. Protein-energy deficiency in cancer. In: Baranovsky AYu, editor. Dietetics: Manual 5th edition. St. Petersburg: Piter; 2017. p. 868-74. (Russian).
13. Kurpeshev OK, Mardynsky YuS. Basic principles and methods of radiomodification in radiotherapy. In: Kaprin AD, Mardynsky YuS, editors. Therapeutic Radiology. National leadership. Moscow: GEOTAR-Media; 2018. P. 89-128. (Russian).
14. Brotherhood H, Lange D, Chew BH. Advances in ureteral stents. Transl Androl Urol 2014;3(3):314-9. DOI: 10.3978/j.issn.2223-4683.2014.06.06.
15. Boyko AV, Korytova LI, Oltarzhevskaya ND, editors. Targeted drug delivery in the treatment of cancer patients. Moscow: Special Medical Book Publisher; 2013. 200 p. (Russian).
For citation: Boyko AV, Dunaeva EA, Demidova LV, Alekseev BYа, Leont’ev AV, Dubovetskaya OB, Serova LG. Radiotherapy for Patients with Hydronephrosis-Induced Cervical Cancer. Medical Radiology and Radiation Safety. 2019;64(4):41–47. (Russian).
PDF (RUS) Full-text article (in Russian)